Farmas USA

Jefferies emite recomendación de compra y fija el precio objetivo en 8$....

http://investorwand.com/recommendations/viewcompany/2354

ARRY

QCOR

Mizuho reiterated Questcor Pharma (QCOR) coverage with Buy rating and price target $84
Previous price target: $65

84$!!
Pues estos de Mizuho valoran según sopla el viento. No puede ser que tras los resultados de hace 12 días valoren a 65$ y hoy pongan un 85$ sin que haya habido ningua novedad que lo justifique. Sencillamente ha llegado a los 65$ y lo suben. Que poca coherencia. Claro que creo que Qcor se va los 84$ sin problemas.

Con información actualizada.
AMRN

INO

http://www.streetinsider.com/Earnings/Inovio+Pharmaceuticals%2C+Inc.+%28INO%29+Doubles+Q2+Loss+to+6cShare%3B+Issues+Update/8589855.html?si_client=intbro

Gráficos a cierre del viernes de ARRY y THLD...

Un saludo

Cellceutix Clinical Study on its Anti-Psoriasis Drug Prurisol™ to Commence

Company beginning process to move to national securities exchange

Beverly, MA— (August 12, 2013) -- Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the Company is on track to commence a clinical study for its anti-psoriasis drug Prurisol™. The Company has completed and submitted all regulatory documents necessary for the clinical study and anticipates receiving the regulatory documents this week allowing for the importation of Prurisol™ into Europe to begin the clinical study.

"We are pleased to inform shareholders that we have now completed the regulatory matters necessary for a clinical study of Prurisol and that we have been notified by our contract manufacturer, Dr. Reddy's Laboratories (RDY), that Prurisol is ready for shipping to the clinical site," Leo Ehrlich, CEO at Cellceutix (CTIX.OB), stated. "We are planning to have the drug shipped in August and the trial to commence shortly thereafter. The clinical site has been notified to begin patient recruitment. We are optimistic about the potential for Prurisol" to reproduce the laboratory results which showed the drug to effectively eliminate all signs of psoriasis."

In other news, Cellceutix's clinical trial of its anti-cancer drug Kevetrin" is progressing and is presently in the dose escalation phase as maximum tolerated dose (MTD) has not yet been reached. The testing for p21, a biomarker study at the Harvard Cancer Center lab, has not yet begun. Dr. Krishna Menon, Cellceutix's Chief Scientific Officer, commented, "We understand that there were internal priorities at the lab and because these are very sophisticated and complex tests, the process can be detailed and somewhat time consuming. We are hopeful that these important biomarker studies will soon be processed and when they are, we will share those results."

The Company is also pleased to report that it is currently planning to uplist (moving from an over-the-counter stock to a national securities exchange like NASDAQ-CM or NYSE-MKT). "Due to the Company's strong financial backing from our $10 million equity line from Aspire Capital, and further progress in our clinical trials, we are intending to move to a senior exchange," commented Leo Ehrlich, CEO. "Over the coming weeks we will be interviewing for the positions of independent directors to meet the requirements for an uplisting which we hope will increase liquidity and unlock inherent value in our stock. We will be presenting at the Rodman and Renshaw Annual Global Investment Conference in September where we will discuss in detail the Company's progress, growth objectives and plans for 2013-2014."

CTIX

Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its parent company, Advanomics Corporation, has been awarded a second research grant, this time from Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a, the Company's flagship anticancer drug candidate in development for multidrug resistant cancers. The grant, in the amount of $510,000, was awarded to Advanomics Corporation in collaboration with Ecole Polytechnique.
On July 16, the Company announced a research grant from NSERC and NanoQuebec in the amount of $940,000, bringing the total grants received from these distinguished agencies for the development of Adva-27a to $1.45 million.

"We are extremely pleased to have garnered this support from CIHR in addition to the support from NSERC and NanoQuebec to develop our novel cancer drug," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "Their commitment will prove invaluable in the advancement of Adva-27a and provides us a strong foundation for clinical trials."

About Adva-27a

Adva-27a is Advanomics Corporation's and Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancers cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original US patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.

SBFM

Edito: Si alguien tiene conocimiento médicos e interés en la materia, os paso el artículo de la revista Anticancer Research de octubre de 2012, donde habla extensamente el Adva27...
Lo podeis obtener en el enlace de dropbox siguiente: https://www.dropbox.com/sh/j5nzd6ot4n3az01/1-hz8D0PeU